Chinese distributor replaces Boston with Braun:
This article was originally published in Clinica
Executive Summary
US medical technology group Global Medical Products Holdings has found an alternative source of products for its Chinese distribution arm. GMPH's ECOM Shanghai International Trading subsidiary will stop distributing Boston Scientific's products - the latter having established its own direct distribution centre. Instead, it will distribute B Braun's Aesculap vena cava filters and vascular grafts. Additionally, GMPH is planning to set up a coronary circulation research centre at the Zhongshan teaching hospital in Shanghai. The company hopes that its clinical trial capabilities in the US and China will generate business from western medical product firms seeking an entry into the Chinese market.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.